Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Tumor Biology

• Publication date

  2013-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s13277-012-0558-1PMID 23086576
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Feasibility of Enzyme Targeted Activation for Amino Acid/Dipeptide Monoester Prodrugs of Floxuridine; Cathepsin D as a Potential Targeted Enzym

  2012cited by this paper
• Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers

  2012cited by this paper
• Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions

  2011cited by this paper
• Evaluation of kallikrein-related peptidase 5 expression and its significance for breast cancer patients: association with kallikrein-related peptidase 7 expression.

  2011cited by this paper
• Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues

  2010cited by this paper
• Prognostic value and biological role of the kallikrein-related peptidases in human malignancies.

  2010cited by this paper
• KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone

  2010cited by this paper
• Functional Roles of Human Kallikrein-related Peptidases*

  2009cited by this paper
• Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11

  2009cited by this paper
• Expression analysis and study of KLK4 in benign and malignant breast tumours

  2009cited by this paper
• Using kallikrein-related peptidases (KLK) as novel cancer biomarkers

  2009cited by this paper
• Kallikrein-related peptidases

  2008cited by this paper
• Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers.

  2008cited by this paper
• Analyzing real-time PCR data by the comparative CT method

  2008cited by this paper
• Enhanced Cancer Cell Growth Inhibition by Dipeptide Prodrugs of Floxuridine: Increased Transporter Affinity and Metabolic Stability

  2008cited by this paper
• Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol

  2008cited by this paper
• Human tissue kallikreins: the cancer biomarker family.

  2007cited by this paper
• Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

  2007cited by this paper
• Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

  2007cited by this paper
• Telling Cells How to Die: Docetaxel Therapy in Cancer Cell Lines

  2007cited by this paper
• New insights into the functional mechanisms and clinical applications of the kallikrein‐related peptidase family

  2007cited by this paper
• Breast Cancer Cells Response to the Antineoplastic Agents Cisplatin, Carboplatin, and Doxorubicin at the mRNA Expression Levels of Distinct Apoptosis‐Related Genes, Including the New Member, BCL2L12

  2007cited by this paper
• Docetaxel and Epirubicin as First-Line Treatment for Patients with Metastatic Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial

  2006cited by this paper
• Genomic signatures to guide the use of chemotherapeutics

  2006cited by this paper
• Human tissue kallikrein gene family: applications in cancer.

  2005cited by this paper
• Human tissue kallikreins: physiologic roles and applications in cancer.

  2004cited by this paper
• The Kallikrein Gene 5 Splice Variant 2 Is a New Biomarker for Breast and Ovarian Cancer

  2004cited by this paper
• The emerging roles of human tissue kallikreins in cancer

  2004cited by this paper
• mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin

  2004cited by this paper
• Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

  2003cited by this paper
• Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer.

  2002cited by this paper
• Characterization of androgen receptor and nuclear receptor co‐regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3

  2002cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4.

  2000cited by this paper
• Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.

  1995cited by this paper
• Cell-growth quantitation methods for the evaluation of antiestrogens in human breast cancer cells in culture.

  1992cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper

• Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer

  2018cites this paper
• KLK14 (kallikrein-related peptidase 14)

  2018cites this paper
• Prognostic value of the kallikrein-related peptidase 5 in hepatocellular carcinoma

  2017cites this paper
• The kallikrein-related peptidase family: Dysregulation and functions during cancer progression.

  2016cites this paper
• Gene expression profiling for targeted cancer treatment

  2015cites this paper
• The role of kinin receptors in cancer and therapeutic opportunities.

  2014cites this paper
• Vitamin C enhances anticancer activity in methotrexate-treated Hep3B hepatocellular carcinoma cells

  2014cites this paper
• Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer

  2014cites this paper
• Family History of Breast Cancer Predicts Breastmilk Protein Expression

  2014cites this paper
• Reliable housekeeping gene combination for quantitative PCR of lymph nodes in patients with prostate cancer.

  2013cites this paper